Ngoh Adeline, McTague Amy, Wentzensen Ingrid M, Meyer Esther, Applegate Carolyn, Kossoff Eric H, Batista Denise A, Wang Tao, Kurian Manju A
Neurosciences Unit, Developmental Neurosciences, University College London, Institute of Child Health, London, UK; Department of Neurology, Great Ormond Street Hospital, London, UK.
Dev Med Child Neurol. 2014 Nov;56(11):1124-8. doi: 10.1111/dmcn.12450. Epub 2014 Mar 29.
Homozygous deletions of chromosome 20p12.3, disrupting the promoter region and first three coding exons of the phospholipase C β1 gene (PLCB1), have previously been described in two reports of early infantile epileptic encephalopathy (EIEE). Both children were born to consanguineous parents, one presented with infantile spasms, the other with migrating partial seizures of infancy. We describe an infant presenting with severe intractable epilepsy (without a specific EIEE electroclinical syndrome diagnosis) and neurodevelopmental delay associated with compound heterozygous mutations in PLCB1. A case note review and molecular genetic investigations were performed for a child, approximately 10 months of age, admitted to Johns Hopkins University Hospital for developmental delay and new-onset seizures. The patient presented at 6 months of age with developmental delay, followed by the onset of intractable, focal, and generalized seizures associated with developmental regression from 10 months of age. Presently, at 2 years of age, the child has severe motor and cognitive delays. Diagnostic microarray revealed a heterozygous 476kb deletion of 20p12.3 (encompassing PLCB1), which was also detected in the mother. The genomic breakpoints for the heterozygous deletion were determined. In order to investigate the presence of a second PLCB1 mutation, direct Sanger sequencing of the coding region and flanking intronic regions was undertaken, revealing a novel heterozygous intron 1 splice site variant (c.99+1G>A) in both the index individual and the father. Advances in molecular genetic testing have greatly improved diagnostic rates in EIEE, and this report further confirms the important role of microarray investigation in this group of disorders. PLCB1-EIEE is now reported in a number of different EIEE phenotypes and our report provides further evidence for phenotypic pleiotropy encountered in early infantile epilepsy syndromes.
此前在两份关于早发性婴儿癫痫性脑病(EIEE)的报告中描述过20号染色体p12.3区域的纯合缺失,该缺失破坏了磷脂酶Cβ1基因(PLCB1)的启动子区域和前三个编码外显子。两名患儿的父母均为近亲结婚,其中一名表现为婴儿痉挛症,另一名表现为婴儿期游走性部分性发作。我们描述了一名患有严重难治性癫痫(未确诊为特定的EIEE电临床综合征)且伴有PLCB1复合杂合突变的婴儿,同时伴有神经发育迟缓。对一名约10个月大因发育迟缓及新发癫痫发作入住约翰·霍普金斯大学医院的患儿进行了病例记录回顾和分子遗传学调查。该患者6个月大时出现发育迟缓,10个月大时开始出现难治性局灶性和全身性癫痫发作,并伴有发育倒退。目前,患儿2岁,存在严重的运动和认知发育迟缓。诊断性微阵列检测发现20p12.3区域存在一个杂合的476kb缺失(包含PLCB1),其母亲也检测到该缺失。确定了杂合缺失的基因组断点。为了研究是否存在第二个PLCB1突变,对编码区和侧翼内含子区域进行了直接桑格测序,结果显示先证者及其父亲均存在一个新的杂合内含子1剪接位点变异(c.99+1G>A)。分子遗传学检测技术的进步极大地提高了EIEE的诊断率,本报告进一步证实了微阵列检测在这组疾病中的重要作用。目前已在多种不同的EIEE表型中报道了PLCB-1相关的EIEE,我们的报告为早发性婴儿癫痫综合征中出现的表型多效性提供了进一步证据。